论文部分内容阅读
目的评价赖脯胰岛素(Lispro)对糖尿病患者的疗效与安全性。方法2003-112004-07对中山大学附属第一医院的40例糖尿病患者用Lispro治疗前后测定血糖、糖化血红蛋白,并记录Lispro用量、低血糖发生率。结果40例患者入选,39例完成观察。治疗12周后,患者的空腹血糖、标准餐后1h血糖、2h血糖的平均值分别下降了1·12mmol/L、2·37mmol/L和1·92mmol/L;GHbA1c平均值下降1·45%;每天所需Lispro剂量与治疗前常规重组人胰岛素相同,低血糖的发生率较前明显减少。结论Lispro在改善糖尿病患者的血糖控制的同时低血糖发生率低。
Objective To evaluate the efficacy and safety of Lispro in diabetic patients. Methods 2003-112004-07 40 patients with diabetes in the First Affiliated Hospital of Sun Yat-sen University were measured before and after Lispro treatment of blood glucose, glycosylated hemoglobin, and Lispro dosage, the incidence of hypoglycemia. Results 40 patients were enrolled and 39 patients completed the observation. After 12 weeks of treatment, the average fasting blood glucose, standard 1h postprandial blood glucose and 2h blood glucose decreased by 1.12mmol / L, 2.37mmol / L and 1.92mmol / L, respectively, while the mean GHbA1c level decreased by 1.45% The daily dose of Lispro required was similar to that of conventional recombinant human insulin before treatment, and the incidence of hypoglycemia was significantly reduced compared with that before treatment. Conclusion Lispro improves the glycemic control in diabetic patients with low incidence of hypoglycemia.